miRNA-93对结肠癌HT-29细胞株化疗敏感性的影响

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (9): 795-800.

miRNA-93对结肠癌HT-29细胞株化疗敏感性的影响

1 100076 北京北京航天总医院普外科

2 100176 首都医科大学附属北京同仁医院肿瘤中心
3 100871 北京大学前沿交叉学科研究院生命科学联合中心

收稿日期:2018-06-15 修回日期:2018-07-22 出版日期:2018-09-30 发布日期:2018-11-28

Effect of miRNA-93 on chemosensitivity of colon cancer cell line HT-29

Department of General Surgery， General Hospital of Spaceflight Hospital， Beijing 100076， China

Received:2018-06-15 Revised:2018-07-22 Online:2018-09-30 Published:2018-11-28

摘要/Abstract

摘要： 目的探讨miR-93与结肠癌HT-29细胞株对氟尿嘧啶（5-FU）敏感性的影响及可能机制。方法 miR-93抑制物转染HT-29细胞，同时设置空白对照组和阴性对照组（NC），采用MTT法检测细胞增殖活性。流式细胞术、Transwell细胞侵袭实验和划痕实验分别检测miR-93抑制物组、空白对照组和NC组HT-29细胞凋亡、侵袭和迁移。双荧光素酶报告实验验证PTEN与miR-93的关系。采用实时荧光定量PCR（QPCR）检测3组细胞miR-93表达，以及对p-VEGFR2、p-Akt、PTEN mRNA表达的影响。结果 miR-93抑制物组中miR-93的相对表达量为0.40±0.05，显著低于空白对照组和NC组的1.13±0.08、1.12±0.09，差异有统计学意义（P＜0.05）。经1、4、16、64、256 μg／ml的5-FU处理后，miR-93抑制物组HT-29细胞的增殖抑制率高于同浓度下NC组和空白对照组，差异有统计学意义（P＜0.05）。经16 μg／ml 5-FU处理后，miR-93抑制物组HT-29细胞凋亡率、侵袭率和愈合率分别为（52.75±7.44）％、（45.76±15.85）％、（12.64±3.29）％，与空白对照组和NC组比较，差异有统计学意义（P＜0.05）。双荧光素酶报告实验分析PTEN可能是miR-93的下游靶基因。miR-93抑制物组p-VEGFR2、p-Akt和PTEN表达水平分别为1.28±0.09、0.85±0.08、1.22±0.09，与空白对照组和NC组比较，VEGFR2和Akt磷酸化水平下调，PTEN表达上调。结论下调miR-93可以增加PTEN的表达，抑制VEGFR-2和Akt磷酸化水平，从而提高结肠癌细胞对5-FU的敏感性。

关键词: 结肠癌, 微小核糖核酸, 5-FU, 敏感性, PTEN

Abstract: Objective To investigate the effect of miR-93 and the sensitivity of colon cancer HT-29 cells on 5-FU and its possible mechanism. Methods miR-93 inhibitor was transfected into HT-29 cells， and blank control group and negative control group （NC） were also set up. Cell proliferation was detected by MTT assay. The apoptosis， invasion and migration activities of HT-29 cells in the miR-93 inhibitor group， blank control group and NC group were detected by flow cytometry， Transwell cell invasion test and scratch test respectively. Double luciferase reporter gene method was used to verify the relationship between PTEN and miR-93. Real-time fluorescence quantitative PCR （QPCR） was used to detect the expression of miR-93 and the effect on the expression of p-VEGFR2， p-Akt and PTEN mRNA in the three groups. Results The relative expression of miR-93 in the miR-93 inhibitor group was 0.40±0.05， significantly lower than that in the blank control group and NC group （1.13±0.08，1.12±0.09）， and the difference was statistically significant （P＜0.05）. The proliferation inhibition rate of HT-29 cells treated with 1， 4， 16， 64， 256 μg／ml 5-FU in miR-93 inhibitor group was higher than that in the NC group and the blank control group （P＜0.05）. The apoptosis rate， invasion rate and healing rate of HT-29 cells treated with 16 μg／ml 5-FU in the inhibitor group were （52.75 ±7.44）％，（45.76 ±15.85）％，（12.64 ±3.29）％ respectively， which were significantly different from those in the control group and NC group （P＜0.05）. PTEN might be a target protein of miR-93 which was verified by the dual luciferase reporter gene system. The expression levels of p-VEGF R2， p-Akt and PTEN in HT-29 cells treated with inhibitor of miR-93 were 1.28±0.09，0.85±0.08 and 1.22±0.09， respectively. Compared with control group and NC group， the phosphorylation levels of VEGFR2 and Akt were down-regulated and the expression of PTEN was up-regulated. Conclusion Down-regulation of miR-93 can increase the expression of PTEN， inhibit the phosphorylation of VEGFR-2 and Akt， and thus enhance the sensitivity of colon cancer cells to 5-FU.

Key words: Colon cancer, microRNAs, 5-FU, Sensitivity, PTEN

苏超云, 施奕君, 刘丹, 魏庆忠.

miRNA-93对结肠癌HT-29细胞株化疗敏感性的影响 [J]. 临床肿瘤学杂志, 2018, 23(9): 795-800.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	王杰军，李　睿. ＮＣＣＮ成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[2]	崔传亮，迟志宏，袁香庆，斯　璐，盛锡楠，郭　军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[3]	高亚杰¹，关小倩¹，杨海林¹，张　阳²，欧阳学农³，杨建伟⁴，陈　焰⁵,徐建明⁶，赵宣良⁷，王宝成⁸，刘文超⁹，张贺龙¹⁰，南克俊¹¹，王湘辉¹² . 注射用左亚叶酸钙联合治疗晚期胃癌和结直肠癌的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 47 .
[4]	徐卫国¹，杨小青²，郝世柱¹，宋纪宁¹，张鹏东¹，胡潺潺¹，王文雅¹. 大肠癌组织中Ｎｅｕｒｏｐｉｌｉｎ-１的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[5]	徐晓明¹，唐金海¹，刘万花²，郑凯尔²，秦建伟¹，赵祥生¹，张　彤³. 触诊阴性乳腺癌的定位方法与同期手术治疗[J]. 临床肿瘤学杂志, 2009, 14(1): 43 .
[6]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .
[7]	张　宾¹，李　畅¹，种道群¹，郭永立¹，陈文明¹，王家富². ＰＴＥＮ和ＢＡＧ-１蛋白在子宫内膜样腺癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(1): 34 .
[8]	钱　莘¹，丁金勇²，吕　军¹，陈正堂². ＣＣＡ＋ＳＰ-Ｃ＋细胞和ＣＤ１３３＋细胞在人肺腺癌组织分布的初步研究[J]. 临床肿瘤学杂志, 2009, 14(1): 6 .
[9]	林文照，林英城，王鸿彪，曾　德，林　懿，林　雯，杜彩文. 雷莫司琼崩解片防治化疗所致恶心呕吐的临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 59 .
[10]	杨　斌，陈赛英，史佃云，张佃乾. 宫颈癌术前介入化疗前后组织中Ｓｕｒｖｉｖｉｎ、Ｃａｓｐａｓｅ-３和Ｃａｓｐａｓｅ-７的表达变化及意义[J]. 临床肿瘤学杂志, 2009, 14(1): 39 .